09:20pm Thursday 21 September 2017

Pattern Recognition Receptors May Be Potent New Drug Targets for Immune-Mediated Diseases

Significant advances in understanding the role that the cytokine-mediated JAK/STAT signaling network and pattern recognition receptors (PRRs) play in regulating immune responses and their potential as novel targets for developing potent new therapies are presented in a Review article in Journal of Interferon & Cytokine Research (JICR) from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal of Interferon & Cytokine Research website until November 15, 2014.

Brendan John Jenkins, MIMR-PHI Institute of Medical Research (Clayton, Victoria, Australia), reviews the latest research and highlights key findings that help explain how cross-talk between cell signaling networks mediated by cytokines and PRRs can impact the development of a variety of disease processes. The authors describe the potential therapeutic implications of targeting these critical networks in the article “Transcriptional Regulation of Pattern Recognition Receptors by JAK/STAT Signaling, and the Implications for Disease Pathogenesis.”

“Dr. Jenkins provides an important new perspective on the role of pattern recognition receptors in disease pathogenesis,” says JICR Co-Editor-in-Chief Thomas A. Hamilton, PhD, Chairman, Department of Immunology, Cleveland Clinic Foundation, Ohio.

About the Journal
Journal of Interferon & Cytokine Research (JICR), led by Co-Editors-in-Chief Ganes C. Sen, PhD, Chairman, Department of Molecular Genetics, Cleveland Clinic Foundation, and Thomas A. Hamilton, PhD, Chairman, Department of Immunology, Cleveland Clinic Foundation, is an authoritative peer-reviewed journal published monthly online with Open Access options and in print that covers all aspects of interferons and cytokines from basic science to clinical applications. JICR is an official journal of the International Cytokine & Interferon Society. Complete tables of content and a sample issue may be viewed on the Journal of Interferon & Cytokine Research website.

About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Viral Immunology, AIDS Research and Human Retroviruses, and DNA and Cell Biology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.


Share on:
or:

Health news